TNF Inhibition in the Treatment of Psoriatic Disease: New Findings in Clinical Research

A supplement to Skin & Allergy News.
Supported by an unrestricted educational grant from Amgen and Wyeth. This supplement is jointly sponsored by the Skin Disease Education Foundation.
Highlights of presentations that took place at the Skin Disease Education Foundation's International Psoriasis Symposium held on June 19, 2003, in New York.
The Skin & Allergy News supplement, “TNF Inhibition in the Treatment of Psoriatic Disease: New Findings in Clinical Research” is recognized by the American Academy of Dermatology for 1 hour of AAD Category 1 credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award.

•Contents
•Target Audience
•Educational Needs
•Learning Objectives
•CME Recognition

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 11.

Contents

The Role of TNF in Psoriasis: Untangling the Cytokine Web
Brian J. Nickoloff, MD, PhD
Professor of Microbiology and Immunology
Director, Oncology Institute
Deputy Director, Cardinal Bernadin Cancer Centre
Professor and Associate Chairman of Pathology
Director, Skin Cancer Research Laboratories
Loyola University Medical Center
Maywood, IL
Consultant: Amgen, Inc. He discusses the investigational use of TNF-targeting agents in the Treatment of Psoriasis.

Newest Biologic Option for Psoriasis on the Horizon: Overview of U.S. Phase III Pivotal Trial Results
David M. Pariser, MD
Professor, Department of Dermatology
Eastern Virginia Medical School
Norfolk
Clinical Grants: Abbott Laboratories, Amgen, Inc., Biogen, Inc., Centocor, Inc., Genentech, Inc. Consultant: Amgen, Inc., Biogen, Inc., Centocor, Inc., Genentech, Inc. He discusses the investigational use of etanercept in the treatment of moderate to severe psoriasis.

Gloval Long-Term Safety Update on Fully Human, Soluble Receptor TNF Antagonist
Alice B. Gottlieb, MD, PhD
Director, Clinical Research Center
W.H. Conzen Chair in Clinical Pharmacology
Professor of Medicine, University of Medicine
and Dentistry of New Jersey
Robert Wood Johnson Medical School
New Brunswick
Clinical Grants: Johnson & Johnson, XOMA LLC., Abbott Laboratories, Ligand Pharmaceuticals, Inc., Amgen , Inc., Biogen, Inc., CellGate, Inc., Centocor, Inc., Genentech, Inc., QUATRx Pharmaceuticals Company, and Schering-Plough Corporation. Consultant: Novartis AG, Wyeth Pharmaceuticals, Eisai Inc., and Celgene Corporation. Financial Interest: Telik, Inc.

Target Audience

This activity has been developed for dermatologists and other healthcare professionals involved in the treatment of psoriasis.

Educational Needs

Psoriasis is a common dermatologic disease that profoundly affects the lives of many patients. Those with mild disease often respond to well-tolerated topical medications. However, the treatments available for patients with moderate to severe disease are not always effective and are associated with serious systemic toxicity. The need for a more effective, less serious modality for managing patients has been at the forefront of research efforts in clinical dermatology. The discovery of the role of tumor necrosis factor (TNF) in psoriasis has allowed the development of anti-TNF treatments. One of these, etanercept, a patient-administered injectable medication, is currently approved by the U.S. Food and Drug Administration for the treatment of another TNF-mediated disease, rheumatoid arthritis. Etanercept has been used in clinical trials in patients with psoriasis. This activity updates dermatologists and other health care professionals who treat patients with psoriasis on the latest information concerning etanercept's mechanism of action, efficacy, and safety.

Learning Objectives

Upon completion of this activity, participants should be able to discuss:

• The role of tumor necrosis factor in psoriatic disease.

• What is currently known and proposed about the mechanism of action of TNF inhibition in the treatment of psoriasis.

• The clinical data currently available on the efficacy of etanercept in psoriatic disease.

• Summarize the adverse side-effects that are avoided by using subantimicrobial doses of doxycycline.

• The safety issues relating to etanercept use and clinical data regarding safety.

CME Recognition

The Skin & Allergy News supplement, “TNF Inhibition in the Treatment of Psoriatic Disease: New Findings in Clinical Research” is recognized by the American Academy of Dermatology for 1 hour of AAD Category 1 credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award.

This program was developed in accordance with the Accreditation Council for Continuing Medical Education guidelines.

Term of Approval: December 2003-November 2004

Copyright © 2003 by International Medical News Group

---